Reverse DCF
What growth rate is priced into Medline Inc. Class A Common Stock (MDLN)?
At the current market price of $35.23, a reverse DCF implies Medline Inc. Class A Common Stock (MDLN) must grow revenue about 7.0% per year for the next decade (10.4% in year one) to be worth what it trades for — holding margins, taxes, reinvestment, and the discount rate fixed at the model's baseline assumptions.
Market price
$35.23
Implied growth (yr 1)
10.4%
Implied 10-yr CAGR
7.0%
Medline Inc. Class A Common Stock (MDLN) reverse DCF FAQ
What revenue growth rate is priced into Medline Inc. Class A Common Stock (MDLN)?
At the current market price of $35.23, a reverse DCF implies Medline Inc. Class A Common Stock's revenue must grow about 7.0% per year for the next ten years (starting at 10.4% in year one) to justify the price — holding margins, taxes, reinvestment, and the discount rate at the model's baseline assumptions.
What is a reverse DCF?
A regular DCF turns growth assumptions into a fair value. A reverse DCF inverts that: it holds every other assumption fixed and solves for the single revenue-growth path that makes intrinsic value equal the current market price. The result is the growth the market is already paying for — a hurdle you can judge the business against.
How does the implied growth compare with the model's own MDLN forecast?
The forward DCF for Medline Inc. Class A Common Stock estimates a fair value of $35.31 per share, implying MDLN is undervalued at the $35.23 market price. If the market-implied growth is well above what the forward model assumes, the price embeds more optimism than the fundamentals-anchored forecast — and vice versa.
How this MDLN implied growth is solved
The engine takes the same 10-year DCF used for the Medline Inc. Class A Common Stock fair-value estimate — margins converging to Damodaran industry benchmarks, year-by-year WACC, a reinvestment rate tied to sales-to-capital efficiency — and inverts it: instead of projecting growth to get a value, it bisects on the starting revenue-growth rate, re-running the valuation until intrinsic value matches the market price. The implied path follows the same moat-scored convergence toward the 2% terminal growth rate that the forward model uses.
The interactive version lets you change what is held fixed — margins, convergence timing, industry benchmarks — and overlays the market-implied growth path on your own editable forecast, so you can see exactly where your expectations and the market's diverge.
The implied growth re-solves when Medline Inc. Class A Common Stock files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last solved 2026-08-07.